Skip to main content

Vantas Valera Pharmaceuticals - Treatment for Prostate Cancer

Vantas is a long-acting implant designed for the continuous 12-month administration of histrelin, a synthetic nonapeptide agonist of luteinizing hormone-releasing hormone (LHRH). Vantas is indicated for the palliative treatment of advanced prostate cancer.

Vantas (histrelin) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.